Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 12/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68481 | 0.83 | BCHE (0.68) | BCHECYP2D6CYP4F2CYP4A11KDM1A | |
| SCHEMBL91436 | 0.81 | BCHE (0.64) | BCHECYP2D6 | |
| SCHEMBL2018777 | 0.81 | HTR2A (0.51) | CYP2D6KDM1AMAOB | |
| SCHEMBL5215124 | 0.77 | BCHE (0.66) | BCHECYP2D6CYP4F2CYP4A11MAOB | |
| SCHEMBL5947384 | 0.74 | BCHE (0.80) | BCHECYP2D6CYP4F2CYP4A11 | |
| SCHEMBL17210775 | 0.74 | CYP4F2 (0.69) | BCHECYP2D6CYP4F2CYP4A11MAOB | |
| SCHEMBL21583899 | 0.74 | BCHE (0.66) | BCHECYP2D6CYP4F2CYP4A11MAOB | |
| SCHEMBL5212656 | 0.73 | BCHE (0.65) | BCHECYP2D6CYP4F2CYP4A11MAOB | |
| SCHEMBL19532618 | 0.73 | BCHE (1.00) | BCHE | |
| SCHEMBL15890882 | 0.73 | CYP2D6 (0.66) | BCHECYP2D6CYP4F2CYP4A11MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129427-B2 | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-03-06 | — | — | US | disclosed |
| US-20110046129-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046129-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | CACNA1A, CACNA1I, KCNN2 | BCHE 2604/4885CYP2D6 3730/4885CYP4F2 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.